Ultragenyx Pharmaceutical Inc.
RARE
$39.34
$0.090.23%
| Weiss Ratings | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.01 | |||
| Price History | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.70% | |||
| 30-Day Total Return | -8.58% | |||
| 60-Day Total Return | -13.35% | |||
| 90-Day Total Return | -22.85% | |||
| Year to Date Total Return | -4.40% | |||
| 1-Year Total Return | -16.95% | |||
| 2-Year Total Return | -3.41% | |||
| 3-Year Total Return | -38.23% | |||
| 5-Year Total Return | 16.39% | |||
| 52-Week High % Change | -34.84% | |||
| 52-Week Low % Change | 6.27% | |||
| Price | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $60.37 | |||
| 52-Week Low Price | $37.02 | |||
| 52-Week Low Price (Date) | Jun 18, 2024 | |||
| 52-Week High Price (Date) | Sep 16, 2024 | |||
| Valuation | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.64B | |||
| Enterprise Value | 3.81B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.34 | |||
| Earnings Per Share Growth | -23.87% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.72 | |||
| Price/Book (Q) | 14.25 | |||
| Enterprise Value/Revenue (TTM) | 6.80 | |||
| Price | $39.34 | |||
| Enterprise Value/EBITDA (TTM) | -7.62 | |||
| Enterprise Value/EBIT | -7.11 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 95.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 415 483 8800 | |||
| Address | 60 Leveroni Court Novato, CA 94949 | |||
| Website | www.ultragenyx.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -95.67% | |||
| Profit Margin | -101.59% | |||
| Management Effectiveness | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -22.37% | |||
| Return on Equity | -- | |||
| Income Statement | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 560.23M | |||
| Total Revenue (TTM) | 560.23M | |||
| Revenue Per Share | $5.86 | |||
| Gross Profit (TTM) | -554.35M | |||
| EBITDA (TTM) | -500.43M | |||
| EBIT (TTM) | -535.97M | |||
| Net Income (TTM) | -569.18M | |||
| Net Income Avl. to Common (TTM) | -569.18M | |||
| Total Revenue Growth (Q YOY) | 29.42% | |||
| Earnings Growth (Q YOY) | -8.28% | |||
| EPS Diluted (TTM) | -6.34 | |||
| EPS Diluted Growth (Q YOY) | 8.20% | |||
| Balance Sheet | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 610.03M | |||
| Cash Per Share (Q) | $6.38 | |||
| Total Current Assets (Q) | 817.12M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 262.30M | |||
| Current Ratio (Q) | 2.374 | |||
| Book Value Per Share (Q) | $2.76 | |||
| Total Assets (Q) | 1.50B | |||
| Total Current Liabilities (Q) | 344.15M | |||
| Total Debt (Q) | 910.01M | |||
| Total Liabilities (Q) | 1.24B | |||
| Total Common Equity (Q) | 255.30M | |||
| Cash Flow | RARE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -17.77M | |||
| Cash from Financing (TTM) | 399.24M | |||
| Net Change in Cash (TTM) | -35.24M | |||
| Levered Free Cash Flow (TTM) | -207.49M | |||
| Cash from Operations (TTM) | -414.19M | |||
